BCR and acute lymphoblastic leukemia: Ponatinib is very efficient, as proven by the pivotal phase 2 ponatinib Ph+ ALL and CML Evaluation (PACE) trial, which evaluated its efficacy at a starting dose of 45 mg once daily in patients resistant/intolerant to dasatinib or nilotinib due to their harboring the BCR-ABL1 T315I mutation, with durable and meaningful clinical responses in the heavily pretreated patients [82].